Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

ITCI Jan 2022 2.500 put

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
0.33000.0000 (0.00%)
At close: 06:51AM EST
Advertisement
Full screen
Previous Close0.3300
Open0.2200
Bid0.0000
Ask4.8000
Strike2.50
Expire Date2022-01-21
Day's Range0.2200 - 0.3300
Contract RangeN/A
Volume6
Open Interest3
  • GuruFocus.com

    Penbrook Management LLC Buys Cohu Inc, Kulicke & Soffa Industries Inc, PubMatic Inc, Sells ...

    New York, NY, based Investment company Penbrook Management LLC (Current Portfolio) buys Cohu Inc, Kulicke & Soffa Industries Inc, PubMatic Inc, Chevron Corp, Intra-Cellular Therapies Inc, sells Nuance Communications Inc, Aspen Group Inc, The One Group Hospitality Inc, Landmark Infrastructure Partners LP, Global Partners LP during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Penbrook Management LLC.

  • GlobeNewswire

    Intra-Cellular Therapies Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

    NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the completion of its previously announced underwritten public offering of 9,523,810 shares of its common stock at a public offering price of $42.00 per share. In addition, the underwriters have exercised in full their option to purchase an additional 1,42

  • GlobeNewswire

    Intra-Cellular Therapies Prices Public Offering of Common Stock

    NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the pricing of its previously announced underwritten public offering of 9,523,810 shares of its common stock at a public offering price of $42.00 per share. All of the shares in the offering will be sold by Intra-Cellular Therapies, with gross proceeds to

Advertisement
Advertisement